Skip to main content

Table 4 Overview of immune evasion capacities for current VOCs against convalescent sera

From: A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants

VOC

Neutralization capacity against wild-type/D614G strain/Victoria virus

Assay used

Reference

B.1.1.7 (Alpha)

2.9-fold (↓)

FRNT50 assay

[60]

B.1.351 (Beta)

Triple mutation: 6.8-fold (↓↓) and 5-fold (↓↓) reduction

B.1.351: 13.3-fold (↓↓↓), 9.4-fold (↓↓↓), 11 to 33-fold (↓↓↓)

FRENT assay, Pseudovirus assay

[55, 63, 64, 81, 83]

P.1 (Gamma)

3.1-fold (↓↓)

FRENT assay

[63]

B.1.617.2 (Delta)

4-6 fold reduction in neutralization capacity compared to alpha and D614G variant (↓↓)

FRNT50 assay

[84]

  1. VOC variants of concern; = and arrows indicate fold-reductions in neutralizing activity compared to control strain. =: no reduction; ↓: 1–3-fold reduction; ↓↓: 3–7-fold reduction; ↓↓↓: > 7-fold reduction